Ocular Therapeutix

OCUL Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$8.49

+1.92% today

52W: $5.80 – $16.44

52W Low: $5.80 Position: 25.3% 52W High: $16.44

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

35.58x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.8B

Market Capitalization

Revenue Growth

-22.4%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-54.85%

Return on Equity

Beta

0.95

Market sensitivity

Short Interest

10.92%

% of float sold short

Avg. Volume

6,345,337

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

11 analysts

Avg. Price Target

$26.00

+206.24% upside

Target Range

$18.00 – $34.00

About the Company

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 325 Exchange: NGM